Nephros price to book ratio NEPH

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: 3.2×
10-year median: 6.0×
Against its 10-year history: 30th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.0× to 113×
Peer median: 1.9×

Nephros' price to book ratio is 3.2× as of Oct 23, 2026.

That is below its ten-year median of 6.0×, lower than on 70% of days in the last ten years.

Over that time it ranged from 1.0× in Sep 2022 to 113× in Jan 2018.

The median for 6 medical instruments and supplies stocks of a similar size is 1.9×.

Price to book ratio over time

median 6×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.2×	3.0×	5.1×
2025	5.2×	1.9×	6.3×
2024	1.9×	1.8×	4.5×
2023	4.2×	1.5×	4.2×
2022	1.9×	1.0×	4.7×
2021	4.9×	4.9×	10.5×
2020	10.1×	6.0×	22.1×
2019	21.7×	8.0×	21.7×
2018	9.0×	8.1×	113×
2017	92.3×	8.3×	103×
2016	15.0×	4.4×	15.8×
2015	3.5×	3.5×	5.8×
2014	93.5×	17.2×	129×
2013	14.7×	9.4×	52.2×
2012	43.2×	3.9×	49.0×
2011	3.9×	2.4×	9.8×

Against its peers

Companies in Medical - Instruments & Supplies nearest Nephros' size, closest first, today.

Company	Price to book ratio
NEPHNephros	3.2×
APTAlpha Pro Tech	0.9×
KEQUKewaunee Scientific	1.3×
PDEXPro DEX	4.2×
UTMDUtah Medical Products	1.9×
INFUInfuSystem	4.7×
EMBCEmbecta	n/m
Peer median	1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Nephros

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.